Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

Wiley, Diabetes, Obesity and Metabolism, 6(19), p. 831-841, 2017

Journal article published in 2017 by Thomas Nyström, Johan Bodegard

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by